Bicara Therapeutics (BCAX) Operating Expenses (2023 - 2026)

Bicara Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $60.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 44.16% year-over-year to $60.2 million; the TTM figure through Mar 2026 stood at $174.1 million (up 59.98% YoY), while the FY2025 annual figure was $155.6 million, up 88.87% from the prior year.
• Operating Expenses for Q1 2026 stood at $60.2 million, up from $41.1 million in the prior quarter.
• The five-year high for Operating Expenses was $60.2 million in Q1 2026, with the low at $9.5 million in Q3 2023.
• The 4-year median for Operating Expenses is $26.6 million (2024), against an average of $29.2 million.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 171.81% in 2025, then soared 44.16% in 2026.
• Bicara Therapeutics' Operating Expenses stood at $13.7 million in 2023, then jumped by 94.62% to $26.6 million in 2024, then soared by 54.38% to $41.1 million in 2025, then soared by 46.5% to $60.2 million in 2026.
• Business Quant data shows BCAX's Operating Expenses at $60.2 million in Q1 2026, $41.1 million in Q4 2025, and $40.7 million in Q3 2025.